Posts

Garijo’s Plan to Revamp Sanofi: R&D Cleanup, More M&A, and a China Push Explained

on

AZ wins EU nod for camizestrant

on

AstraZeneca licenses EGFR lung cancer drug Zegfrovy from spinoff Dizal for up to $1.5B

on

Hengrui, Kailera’s GLP‑1 Pill Posts Encouraging Efficacy but High Side Effect Rates in Late‑Stage China Trials

on

US lawmakers intensify scrutiny of Chinese clinical trials, raising industry concerns over cost and disruption

on

AstraZeneca seals near $1.8B renal disease pact with CSPC

on

Recent US moves add hurdles to US investments in China biotech

on

Friday Five: FDA steps up to counter China’s clinical‑trial edge, AbbVie buys Apogee, and psychedelics hype yields real data

on

BIO board met with national security, health officials on China’s biotech rise, CEO says (June 2026 news digestable summary)

on

Ollin nets $330M to fund Phase 3 trials of Vabysmo challenger from China (OLN324)

on

Serapha Bio takes flight from Boundless merger with $230M and gene-editing prospect from China

on

As China biotech crackdown calls reverberate in Washington, the pushback gets louder, too Recent efforts in Washington to restrict U.S. investment and partnerships with Chinese biotech firms have triggered a fierce backlash from industry leaders and intensified concerns in Beijing, turning biotech into the latest front in the U.S.-China tech rivalry.

on

Akeso takes center stage at ASCO 2026 as China biotech cements its global arrival

on

Lilly bets $3B+ to add China's Haisco to growing list of partners in five‑program pact – June 2–3, 2026 update

on

China gene editing startup YolTech raises $70M to move CRISPR therapies forward

on

Post-Hoc Live: Jeremy Levin warns of threats to U.S. biotech

on

Globalisation 2.0 | Henlius Completes First Patient Dosed in China for MRCT of pimurutamab (HLX07) Plus serplulimab, Accelerating Global Development

on

Henlius Advances First-in-Class B7-H3 Sialidase Fusion Protein HLX316/E-688 into First-in-Human Phase 1 Trial in China

on

Design Therapeutics’ Friedreich’s Ataxia Data and Vincentage’s Obesity Results from China

on

AACR: Zai Lab's Global Ambitions and Reality Check on China's Biotech Rise

on